Affibody and Asahi Kasei to collaborate in medical application
Affibody AB and Asahi Kasei Corporation today announced a research agreement to develop a product which will enable the selective removal of a target molecule from fluid mixtures.
Affibody will under the agreement develop an Affibody® molecule which will be used as an affinity ligand for removal of the target from mixtures. The high capacity, robustness and high specificity make Affibody molecules ideal affinity capture agents for use in medical applications. Asahi Kasei will develop a medical device utilizing the Affibody® molecule. The product will be an important addition to Asahi Kasei's product portfolio in medical devices.
"This agreement is important for the company and further supports the role of Affibody® molecules in medical applications. We are also very pleased to enter into collaboration with a Japanese partner. Japan is a market where we want to be present and this agreement will strengthen our market presence there. Asahi Kasei is a perfect match for us with their outstanding experience and know -how in the field of separation devices." says Torben Jørgensen, Chief Executive Officer of Affibody.
"The exceptional performance of Affibody® molecules for capturing a specific target will in combination with our separation technology lead to the development of an important new product. This will make it possible to complement our existing product line with a device to perform targeted treatment." says Dr. Shuichiro Ogawa, External Technology Manager, Asahi Kasei.
Other news from the department business & finance
